ACAD 似乎有些冤枉(不是鼓励接飞刀）

病人死的多， 但也少于非治疗病人死亡率的一半， 本来老年Parkinson's 病 死亡率就很高。

一个FDA调查有不知啥样后果。

 

• Acadia regularly monitors the mortality risk for Nuplazid and reports data to the FDA each quarter. Since launch, the overall mortality rate of patients who use Nuplazid is 12.4 deaths per 100 patient years. That's less than half of the 28.2 deaths per 100 patient years that is observed in the PDP population in general.
• The FDA has not identified a specific safety issue that is not already described in Nuplazid's 

所有跟帖： 

• 国会议员具体问道这个公司的药，估计民间投诉不少，FDA不得不再次审查，起码做个样子 -初进大观园- ♂ (0 bytes) () 04/25/2018 postreply 13:57:14